TME
Sponsors
Johannes Gutenberg University Mainz, Harbin Medical University, West China Hospital, Case Comprehensive Cancer Center, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions
ChemoradiotherapyHigh Risk FactorsLocal Advanced Rectal CancerLocally Advanced Rectal CancerRectal CancerRectum CancerTotal Neoadjuvant Treatment
Phase 2
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer
Active, not recruitingNCT04543695
Start: 2020-08-15End: 2025-06-01Target: 255Updated: 2024-03-26
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
NCT04664504
Start: 2020-12-01End: 2025-12-01Target: 150Updated: 2021-06-08
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
Active, not recruitingNCT05253846
Start: 2022-01-25End: 2028-10-30Target: 63Updated: 2025-06-10
Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT
NCT05763927
Start: 2022-09-01End: 2025-04-01Target: 44Updated: 2023-03-10
Phase 3
Phase 4
Unknown Phase
Intraoperative Monitoring of the Pelvic Autonomic Nerves
CompletedNCT01585727
Start: 2012-06-30End: 2018-12-31Updated: 2019-02-27
Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy
NCT03071198
Start: 2017-03-01End: 2021-09-30Target: 1Updated: 2017-03-07
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Active, not recruitingNCT03283540
Start: 2017-09-25End: 2025-08-31Updated: 2025-08-17